Amphotericin B-loaded mannose modified poly(<scp>d</scp>,<scp>l</scp>-lactide-co-glycolide) polymeric nanoparticles for the treatment of visceral leishmaniasis: in vitro and in vivo approaches

Ghosh, Santanu; Das, Suman; De, Asit K.; Kar, Nabanita; Bera, Tanmoy

doi:10.1039/c7ra04951j

Cited by 29 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first and the second heating curves of the DSC measurements are displayed in Figures 5A,B, respectively. The first heating curve (A) of Eu-L showed two endotherm peaks, one at 83 • C and another one at 208 • C. The second heating curve (B) Eu-L showed a glass transition at 143 • C. During the first heating cycle, AmpB had an endotherm peak at 103 and 204 • C, which are also described in the literature (Angra et al, 2009;Ghosh et al, 2017). It is well-known that AmpB starts to degrade at temperatures over 200 • C without melting (Kim et al, 2010).…”

Section: Characterization Of Ampb-eu-l Polyelectrolyte Complex (Id)supporting

confidence: 74%

In situ Gelling Amphotericin B Nanofibers: A New Option for the Treatment of Keratomycosis

Göttel

Lucas

Syrowatka

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The purpose of our research was the development of Amphotericin B-loaded in situ gelling nanofibers for the treatment of keratomycosis. Different formulation strategies were applied to increase the drug load of the sparingly water-soluble Amphotericin B in electrospun Gellan Gum/Pullulan fibers. These include bile salt addition, encapsulation in poly(lactic-co-glycolic acid) (PLGA) nanoparticles and formation of a polymeric Amphotericin B polyelectrolyte complex. The Amphotericin B polyelectrolyte complex (AmpB-Eu L) performed best and was very effective against the fungal strain Issatchenkia orientalis in vitro. The complex was characterized in detail by attenuated total reflection infrared spectroscopy, X-ray powder diffraction, and differential scanning calorimetry. A heat induced stress test was carried out to ensure the stability of the polyelectrolyte complex. To gain information about the cellular tolerance of the developed polyelectrolyte complex a new, innovative multilayered-stratified human cornea cell model was used for determination of the cellular toxicity in vitro. For a safe therapy, the applied ophthalmic drug delivery system has to be sterile. Sterilization by electron irradiation caused not degradation of pure Amphotericin B and also for the bile salt complex. Furthermore, the developed Amphotericin B polyelectrolyte complex was not degraded by the irradiation process. In conclusion, a new polyelectrolyte Amphotericin B complex has been found which retains the antifungal activity of the drug with sufficient stability against irradiation-sterilization induced drug degradation. Furthermore, in comparison with the conventional used eye drop formulation, the new AmpB-complex loaded nanofibers were less toxic to cornea cells in vitro. Electrospinning of the Amphotericin B polyelectrolyte complex with Gellan Gum/ Pullulan leads to the formation of nanofibers with in situ gelling properties, which is a new and promising option for the treatment of keratomycosis.

show abstract

Section: Characterization Of Ampb-eu-l Polyelectrolyte Complex (Id)supporting

confidence: 74%

In situ Gelling Amphotericin B Nanofibers: A New Option for the Treatment of Keratomycosis

Göttel

Lucas

Syrowatka

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Primaquine-loaded nanoparticles were tested, with a 21-fold higher response in terms of drug release and with fewer side effects [129]. Similar results were observed with the use of nanoparticles containing AmB [130]. Pentamidine nanoparticles were also evaluated, and the response was 25-fold higher in terms of drug release and with less side effects [131].…”

Section: New Drug Delivery Systemsmentioning

confidence: 94%

Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems

et al. 2019

View full text Add to dashboard Cite

The incidence of neglected diseases in tropical countries, such as Leishmaniasis and Chagas’s disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health care systems. Both Leishmaniasis and Chagas’s disease are caused by different protozoa and develop diverse symptoms, which depend on the specific species infecting man. Currently available drugs to treat these disorders have limited therapeutic outcomes, frequently due to microorganisms’ drug resistance. In recent years, significant efforts have been made towards the development of innovative drug delivery systems aiming to improve bioavailability and pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of Leishmaniasis and Chagas’s disease, the currently available pharmacological therapies and the new drug delivery systems for conventional drugs.

show abstract

“…50% Cellular Cytotoxicity (CC50) is the concentration at which 50% of the cell population should be killed and IC50 is the 50% inhibitory concentration. It is considered that when SI value is equal to or more than 10, the drug candidate have the promising activity for its intended purpose [38]. Table 5 and fig.…”

Section: Discussionmentioning

confidence: 99%

“…Different concentrations of drugs were added to the respective wells and the well plate was kept in the 5% CO2 incubator for 72 h. After that cell counts were taken using hemocytometer under an inverted microscope. Numbers of amastigotes of untreated controls were compared with the drug treated wells to determine the IC50 values [38].…”

Section: Development Of Drug-resistant Amastigote Strainsmentioning

confidence: 99%

Search for New Antileishmanial Chemotherapeutics

Kar

Ghosh

Kumari

et al. 2018

Int J Pharm Pharm Sci

Self Cite

View full text Add to dashboard Cite

Objective: The objective of this work was to screen a number of compounds for their antileishmanial efficacy and cytotoxicity profiling.Methods: Curry leaf oil, cypress oil and spikenard oil were identified by gas chromatography-mass spectrometry (GC/MS) analysis. Betulinic acid, spikenard oil, cypress oil and curry leaf oil were evaluated for their in vitro antileishmanial activity against Leishmania donovani AG83 wild-type, sodium stibogluconate resistant (SSG-resistant), paromomycin (PMM-resistant) and GE1 field type strains on axenic and cellular amastigote model and compared the results with standard drugs used to treat leishmaniasis. Results:Betulinic acid showed strong antileishmanial activity against wild-type (SI= 192.8), SSG-resistant (SI= 19.3) and GE1 strains (SI= 100), whereas cypress oil has produced highest antileishmanial activity against PMM-resistant strains (SI= 15.09) among all the tested drugs. The data obtained also revealed that cypress oil had the maximum CC50 Conclusion: All tested drugs had antileishmanial property but among them, betulinic acid possess strong antileishmanial activity in case of both wild-type and drug-resistant leishmaniasis.value of 452.9 μl among all standard and tested drugs.

show abstract

Amphotericin B-loaded mannose modified poly(d,l-lactide-co-glycolide) polymeric nanoparticles for the treatment of visceral leishmaniasis: in vitro and in vivo approaches

Abstract: Amphotericin B-loaded mannose modified PLGA nanoparticles are more efficacious in the treatment of visceral leishmaniasis in bothin vitroandin vivomodels than unmodified nanoformulations.

Cited by 29 publications

References 35 publications

In situ Gelling Amphotericin B Nanofibers: A New Option for the Treatment of Keratomycosis

In situ Gelling Amphotericin B Nanofibers: A New Option for the Treatment of Keratomycosis

Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems

Search for New Antileishmanial Chemotherapeutics

Contact Info

Product

Resources

About